Calidi Biotherapeutics (CLDI) Accounts Payables (2021 - 2025)

Calidi Biotherapeutics has reported Accounts Payables for 5 years, with the latest figure at $600000.0 in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables fell 71.04% year-over-year to $600000.0; the trailing twelve-month figure through Dec 2025 stood at $600000.0 (down 71.04% YoY), and the FY2025 full-year result was $600000.0, down 71.04% from the prior year.
• Accounts Payables for Q4 2025 stood at $600000.0, up from $5000.0 in the prior quarter.
• The five-year high for Accounts Payables was $6.8 million in Q3 2024, with the low at $5000.0 in Q3 2025.
• Average Accounts Payables over 5 years is $1.8 million, with a median of $142009.0 recorded in 2023.
• Year-over-year, Accounts Payables soared 4847.52% in 2023 and sank 99.93% in 2025.
• Tracing CLDI's Accounts Payables over 5 years: stood at $63839.0 in 2021, then surged by 3227.12% to $2.1 million in 2022, then plunged by 96.19% to $81000.0 in 2023, then jumped by 2458.02% to $2.1 million in 2024, then tumbled by 71.04% to $600000.0 in 2025.
• The last three Accounts Payables figures came in at $600000.0 (Q4 2025), $5000.0 (Q3 2025), and $12000.0 (Q2 2025), per Business Quant data.

Peer Comparison